https://doi.org/10.4081/mm.2004.3025

CMV DNA e MRNA Pp67 nel monitoraggio del paziente sottoposto a trapianto di midollo osseo

Vol. 19 No. 1 (2004)
Submitted: 25 February 2014
Accepted: 25 February 2014
Published: 30 March 2004
Abstract Views: 497
PDF: 969
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Maria Bonaria Goffi
office@pagepress.org
Primary infection of immunocompetent individuals does not lead to complication, but CMV is a major clinical problem in transplant recipients.Thus, it is important to use sensitive and specific diagnostic techniques to rapidly and accurately detect CMV infection and identify patients at risk of developing CMV disease. In the present study, CMV infection after bone marrow transplantation was monitored by two molecular biology assays: COBAS AMPLICOR CMV MONITOR and NUCLISENS CMV m-RNA pp67. CMV m-RNApp67 assay was found to show positivity later than CMV-DNA MONITOR. The increment of number of copies/ml agreed with the clinical symptoms of CMV infection. The quantitative results of the CMV MONTOR assay was more helpfull to select an antiviral strategy than the qualitative results of NUCLISENS m-RNA pp67 assay.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Goffi, M. B. (2004). CMV DNA e MRNA Pp67 nel monitoraggio del paziente sottoposto a trapianto di midollo osseo. Microbiologia Medica, 19(1). https://doi.org/10.4081/mm.2004.3025

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.